AI-generated summary
The authors tested a combination of the antibody C225, which blocks EGFR activity, and benzoporphyrin-based photodynamic therapy in mice with human ovarian cancer. They report that the combination produced lower mean tumor burden and longer survival than either treatment alone, with synergistic effects. The study used a mouse model with 9 to 19 mice per group.
- Who or what was studied
- Mice with human ovarian cancer (mouse model)
- Limits stated in the abstract
- The study was conducted in mice with small group sizes of 9 to 19 per group, so findings may not apply to humans.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on academic.oup.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photodynamic therapy, Confidence interval, Control group. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.